Circulating Prostate Cancer Progenitor Cell Assay Development

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-08-C-0099
Agency Tracking Number: A08A-041-0388
Amount: $96,765.00
Phase: Phase I
Program: STTR
Awards Year: 2008
Solitcitation Year: 2008
Solitcitation Topic Code: A08-T041
Solitcitation Number: 2008.A
Small Business Information
ANDROBIOSYS, INC.
73 High Street, Buffalo, NY, 14203
Duns: 193493157
Hubzone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Michael Zwick
 CEO
 (716) 860-7920
 mzwick@androbiosys.com
Business Contact
 Michael Zwick
Title: CEO
Phone: (716) 860-7920
Email: mzwick@androbiosys.com
Research Institution
 ROSWELL PARK CANCER INSTITUTE
 Joseph H Jurkowski
 Elm and Carlton Streets
Buffalo, NY, 14263
 (716) 845-2312
 Domestic nonprofit research organization
Abstract
This Phase I contract proposal will evaluate and identify markers associated with prostate cancer progenitor stem cells, that differentiate these cells from adult tissue stem cells and benign prostate progenitor cells. The eventual goal of this work would be to develop a high throughput blood-based assay highly specific for circulating prostate cancer progenitor cells. A cell shed from a tumor must be capable of surviving separate from the microenvironment of the primary tumor, and possess the capacities of proliferation and plasticity, to regenerate a metastasis. These traits essentially describe a cancer stem cell (CSC). Therefore, we propose to develop a technology to identify circulating CSCs, or more accurately the progenitor cells that are their immediate progeny, an approach that should provide a more informative prognostic tool for prediction of aggressiveness and metastatic potential.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government